A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.
Also called NCT02152371
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 300 participants
- Sponsor
- Registry
-
NCT02152371 -
2012-004229-25
-
- Other papers using this trial's data
- Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9)
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Czechia, Hungary, Italy, Puerto Rico, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02152371. Randomized; double masking; primary purpose treatment. Start 2014-05 (registry gives no type); primary completion 2015-10 (actual). Results posted on 2016-12-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes
- Acronym
- AWARD-9
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Dulaglutide
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Insulin Glargine
- Intervention (Drug)
- Metformin
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct02152371- Content hash
621023d9681c302bbb235b8268ac138fdafe97f5a93b223179461aaa74c16e51